Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review

被引:11
作者
Al-Romaima, Abdulbaset [1 ]
Liao, Yinan [1 ]
Feng, Jie [1 ]
Qin, Xihui [1 ]
Qin, Guiming [1 ]
机构
[1] Guangxi Med Univ, Sch Pharmaceut Sci, Shuangyong Rd 22, Nanning 530021, Peoples R China
基金
中国国家自然科学基金;
关键词
Coronavirus disease 2019 (COVID-19); coronavirus; treatment; traditional Chinese medicine (TCM); ACUTE RESPIRATORY SYNDROME; TREATMENT OPTIONS; EBOLA-VIRUS; PREVENTION; SARS; CHLOROQUINE; RIBAVIRIN; INHIBIT; ANTIBIOTICS; DERIVATIVES;
D O I
10.21037/jtd-20-1810
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In December 2019, the coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered. Since its emergence, COVID-19 has been outbreaking rapidly worldwide, where the virus has so far caused the death of hundreds of thousands and infected more than a million, what has been called a pandemic by the World Health Organization (WHO). According to the WHO-Coronavirus disease 2019 Situation Report-142, by June 10, 2020, there are 7,145,539 confirmed cases and 408,025 deaths. There is an urgent need to develop a suitable specific medicine against this novel coronavirus; therefore, scientists and researchers around the world are making great efforts endeavoring to discover an efficient specific medication for COVID-19 treatment. Given the similarity of the novel coronavirus with previous epidemic viruses, namely, the acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), previously tested drugs could potentially work against the novel coronavirus. In this narrative review, we aim to summarize and discuss the effectiveness of current Western medicine and traditional Chinese medicine options for COVID-19 treatment based on the overview of the scientific literature. Some Western medicines including remdesivir, chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, and arbidol, as well as some traditional Chinese medicine (TCM) such as Qingfei Paidu decoction, Yupingfeng, Lianhua Qingwen, and TCM injections have revealed a relative activity against SARS-CoV-2 in vitro, in observational studies, and in clinical trials. However, further extensive studies and clinical trials including double-blind and randomized clinical trials, with a higher number of patients, are necessary to confirm the activity of these medicines. There are several ongoing trials conducted on the drugs of COVID-19, and the results are urgently needed to make a suitable treatment recommendation.
引用
收藏
页码:6054 / 6069
页数:16
相关论文
共 102 条
[1]   Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [J].
Agostini, Maria L. ;
Andres, Erica L. ;
Sims, Amy C. ;
Graham, Rachel L. ;
Sheahan, Timothy P. ;
Lu, Xiaotao ;
Smith, Everett Clinton ;
Case, James Brett ;
Feng, Joy Y. ;
Jordan, Robert ;
Ray, Adrian S. ;
Cihlar, Tomas ;
Siegel, Dustin ;
Mackman, Richard L. ;
Clarke, Michael O. ;
Baric, Ralph S. ;
Denison, Mark R. .
MBIO, 2018, 9 (02)
[2]  
[Anonymous], 2020, FAV IS MOR EFF LOP R
[3]  
[Anonymous], 2020, CHINESE TRADITIONAL
[4]  
[Anonymous], 2015, CRITICAL CARE MED
[5]   The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study [J].
Auyeung, TW ;
Lee, JSW ;
Lai, WK ;
Choi, CH ;
Lee, HK ;
Lee, JS ;
Li, PC ;
Lok, KH ;
Ng, YY ;
Wong, WM ;
Yeung, YM .
JOURNAL OF INFECTION, 2005, 51 (02) :98-102
[6]   Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses A Randomized Clinical Trial [J].
Bacharier, Leonard B. ;
Guilbert, Theresa W. ;
Mauger, David T. ;
Boehmer, Susan ;
Beigelman, Avraham ;
Fitzpatrick, Anne M. ;
Jackson, Daniel J. ;
Baxi, Sachin N. ;
Benson, Mindy ;
Burnham, Carey-Ann D. ;
Cabana, Michael ;
Castro, Mario ;
Chmiel, James F. ;
Covar, Ronina ;
Daines, Michael ;
Gaffin, Jonathan M. ;
Gentile, Deborah Ann ;
Holguin, Fernando ;
Israel, Elliot ;
Kelly, H. William ;
Lazarus, Stephen C. ;
Lemanske, Robert F., Jr. ;
Ly, Ngoc ;
Meade, Kelley ;
Morgan, Wayne ;
Moy, James ;
Olin, Tod ;
Peters, Stephen P. ;
Phipatanakul, Wanda ;
Pongracic, Jacqueline A. ;
Raissy, Hengameh H. ;
Ross, Kristie ;
Sheehan, William J. ;
Sorkness, Christine ;
Szefler, Stanley J. ;
Teague, W. Gerald ;
Thyne, Shannon ;
Martinez, Fernando D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (19) :2034-2044
[7]   Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities [J].
Biot, C ;
Daher, W ;
Chavain, N ;
Fandeur, T ;
Khalife, J ;
Dive, D ;
De Clercq, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (09) :2845-2849
[8]  
Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
[9]   A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [J].
Boulware, David R. ;
Pullen, Matthew F. ;
Bangdiwala, Ananta S. ;
Pastick, Katelyn A. ;
Lofgren, Sarah M. ;
Okafor, Elizabeth C. ;
Skipper, Caleb P. ;
Nascene, Alanna A. ;
Nicol, Melanie R. ;
Abassi, Mahsa ;
Engen, Nicole W. ;
Cheng, Matthew P. ;
LaBar, Derek ;
Lother, Sylvain A. ;
MacKenzie, Lauren J. ;
Drobot, Glen ;
Marten, Nicole ;
Zarychanski, Ryan ;
Kelly, Lauren E. ;
Schwartz, Ilan S. ;
McDonald, Emily G. ;
Rajasingham, Radha ;
Lee, Todd C. ;
Hullsiek, Kathy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :517-525
[10]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]